IOVA vs. SWTX, APGE, IBRX, ACLX, IMCR, IMVT, CGON, DNLI, VCEL, and KYMR
Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Arcellx (ACLX), Immunocore (IMCR), Immunovant (IMVT), CG Oncology (CGON), Denali Therapeutics (DNLI), Vericel (VCEL), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
Iovance Biotherapeutics (NASDAQ:IOVA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
In the previous week, SpringWorks Therapeutics had 3 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 7 mentions for SpringWorks Therapeutics and 4 mentions for Iovance Biotherapeutics. SpringWorks Therapeutics' average media sentiment score of 0.38 beat Iovance Biotherapeutics' score of 0.01 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. 10.4% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
SpringWorks Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Iovance Biotherapeutics presently has a consensus price target of $24.64, suggesting a potential upside of 117.06%. SpringWorks Therapeutics has a consensus price target of $68.00, suggesting a potential upside of 49.81%. Given Iovance Biotherapeutics' higher possible upside, research analysts plainly believe Iovance Biotherapeutics is more favorable than SpringWorks Therapeutics.
Iovance Biotherapeutics received 469 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 74.47% of users gave Iovance Biotherapeutics an outperform vote while only 67.69% of users gave SpringWorks Therapeutics an outperform vote.
SpringWorks Therapeutics' return on equity of -65.69% beat Iovance Biotherapeutics' return on equity.
Summary
Iovance Biotherapeutics beats SpringWorks Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Iovance Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iovance Biotherapeutics Competitors List
Related Companies and Tools
